Immutep Limited 

Immutep Limited, an Australian biotechnology firm established in 1987, is focused on the discovery and development of innovative immunotherapeutic pharmaceuticals. The company's pipeline primarily targets cancer and autoimmune diseases. Its flagship product, eftilagimod alpha (also known as efti or IMP321), is currently in a Phase IIb clinical trial, investigating its efficacy as a chemo-immunotherapy combination for metastatic breast cancer. Additional oncology candidates include TACTI-002, undergoing Phase II trials for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer, and TACTI-003, in Phase IIb trials for HNSCC. The company is also evaluating INSIGHT-003 in a Phase I trial and INSIGHT-005 in a Phase I/IIa trial, both designed for solid tumors. Furthermore, Immutep's portfolio features IMP761, an agonist for lymphocyte activation gene 3 intended for autoimmune conditions; IMP701, an antagonist antibody aimed at stimulating T cell proliferation in cancer; and IMP731, a depleting antibody to remove T cells associated with autoimmunity. Immutep Limited, which was formerly known as Prima BioMed Ltd until its renaming in November 2017, collaborates with various partners such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma, operating from its headquarters in Sydney, Australia.